Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Inhibikase Therapeutics yesterday and set a price target of $8.00.

Jason McCarthy has given his Buy rating due to a combination of factors surrounding IKT-001 and its late-stage development in pulmonary arterial hypertension. He highlights that the Phase 3 IMPROVE-PAH trial is already underway with an FDA-aligned, adaptive design that first measures hemodynamic benefits and then focuses on functional outcomes, which he views as a structured and efficient path to potential approval.

He also emphasizes that IKT-001, as an oral prodrug of imatinib, aims to retain prior efficacy signals seen with imatinib in PAH while reducing the gastrointestinal toxicity that previously limited its use, thereby partially de-risking the program. In addition, he notes the favorable regulatory positioning as a New Molecular Entity under the 505(b)(2) pathway and the substantial capital raised from healthcare-focused investors, which together provide both financial runway and validation for advancing the Phase 3 program, supporting his positive stance on the stock.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.

IKT’s price has also changed slightly for the past six months – from $1.620 to $1.760, which is a 8.64% increase.